1-methylphenol n-propyl ether | 4607-37-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-methylphenol n-propyl ether
• 英文别名: 2-(propyloxy)toluene；2-propoxytoluene；propyl-o-tolyl ether；Propyl-o-tolyl-aether；2-Propyloxy-toluol；Propyl-o-tolylether；o-Kresolpropylather；1-methyl-2-propoxybenzene
• CAS: 4607-37-8
• 化学式: C₁₀H₁₄O
• mdl: MFCD06252260
• 分子量: 150.221
• InChiKey: HKCQYAPIHRALPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-methylphenol n-propyl ether 在 三氯化铝 、 硝基苯 作用下， 生成 4-(3-methyl-4-propoxy-phenyl)-4-oxo-butyric acid ethyl ester
  参考文献：
  名称：

  Bhatt; Nargund; Patel, Journal of the University of Bombay, Science: Physical Sciences, Mathematics, Biological Sciences and Medicine, 1946, vol. 15/3 A, p. 31,37

  摘要：

  DOI：
• 作为产物：
  描述：

  1-碘代丙烷 、 邻甲酚 在 氢氧化钾 作用下， 生成 1-methylphenol n-propyl ether
  参考文献：
  名称：

  Pinette, Justus Liebigs Annalen der Chemie, 1888, vol. 243, p. 32,40

  摘要：

  DOI：

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Chemoselective hydrogenation method catalyzed by Pd/C using diphenylsulfide as a reasonable catalyst poison
  作者：Akinori Mori、Tomoteru Mizusaki、Yumi Miyakawa、Eri Ohashi、Tomoko Haga、Tomohiro Maegawa、Yasunari Monguchi、Hironao Sajiki

  DOI：10.1016/j.tet.2006.09.094

  日期：2006.12

  using Pd/C, we investigated catalyst poison as a controller of the catalyst activity. We found that the addition of Ph2S (diphenylsulfide) to the Pd/C-catalyzed hydrogenation reaction mixture led to reasonable deactivation of Pd/C. By the use of the Pd/C–Ph2S catalytic system, olefins, acetylenes, and azides can be selectively reduced in the coexistence of aromatic carbonyls, aromatic halides, cyano

  尽管Pd / C是最有用的加氢催化剂之一，但Pd / C的高催化剂活性导致难以将其应用于不同类型的可还原官能团之间的化学选择性加氢。为了实现使用Pd / C进行化学选择性加氢，我们研究了催化剂毒物作为催化剂活性的控制剂。我们发现，向Pd / C催化的氢化反应混合物中添加Ph 2 S（二苯硫醚）可导致Pd / C合理失活。通过使用Pd / C–Ph 2 S催化体系，烯烃，乙炔和叠氮化物可以选择性地还原成芳族羰基，芳族卤化物，氰基，苄基酯和N-Cbz（苄氧羰基）保护基。本方法有望作为合成有机化学中通用和实用的化学选择性加氢方法。
• Process for preparation of tamsulosin and its aralkylamine derivatives
  申请人：Jih Hwu Ru

  公开号：US20070015939A1

  公开（公告）日：2007-01-18

  The present invention discloses a new process for the synthesis of tamsulosin and its aralkylamine derivatives, especially (R)-(−)-5-2-[2-(2-alkoxyphenoxy)ethylamino]propyl}-2-alkoxybenzenesulfonamides having the following formula 1 (where R 1 and R 2 represent C 1 -C 4 alkyl groups) and their hydrochloride thereof, and other various pharmaceutical used salts. Tamsulosin hydrochloride (R 1 =Et, R 2 =Me, in its hydrochloride salt form) is an antagonist of α-A adrenoceptors in the prostate. Tamsulosin•HCl occurs as white crystals, which melt with decomposition at approximately 230° C. It is sparingly soluble in water and in methanol, slightly soluble in glacial acetic acid and in ethanol, and practically insoluble in ether.

  本发明公开了一种合成坦洛新及其芳基胺衍生物的新工艺，特别是具有以下化学式1的(R)-(−)-5-2-[2-(2-烷氧基苯氧基)乙基氨基]丙基}-2-烷氧基苯磺酰胺（其中R1和R2代表C1-C4烷基基团）及其盐酸盐，以及其他各种药用盐。坦洛新盐酸盐（R1=Et，R2=Me，在其盐酸盐形式中）是前列腺α-A肾上腺素受体的拮抗剂。坦洛新•HCl呈白色晶体，约在230°C左右分解熔化。它在水和甲醇中溶解度较低，在冰乙酸和乙醇中稍溶，在醚中几乎不溶。
• [EN] BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT<br/>[FR] DÉRIVÉS BENZIMIDAZOLE EN TANT QUE BLOQUEURS SÉLECTIFS DU COURANT DE SODIUM PERSISTANT
  申请人：ALLERGAN INC

  公开号：WO2013101926A1

  公开（公告）日：2013-07-04

  The present invention is directed to methods of treating diseases or conditions mediated by elevated persistent sodium channel, such as ocular disorders, pain, multiple sclerosis, and seizure disorders utilizing a compound of Formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said compound, wherein variables R, R1, R2, R3, R4, R5, m, and n in Formula (I) are as defined herein.

  本发明涉及治疗由持续性钠通道升高介导的疾病或症状的方法，例如眼部疾病、疼痛、多发性硬化和癫痫症，利用化合物I的方法或其药学上可接受的盐或包含该化合物的药物组合物，其中化合物I中的变量R、R1、R2、R3、R4、R5、m和n如本文所定义。